Fiona Forrestal

1.8k total citations · 2 hit papers
17 papers, 1.0k citations indexed

About

Fiona Forrestal is a scholar working on Pharmacology, Pathology and Forensic Medicine and Biological Psychiatry. According to data from OpenAlex, Fiona Forrestal has authored 17 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 5 papers in Pathology and Forensic Medicine and 5 papers in Biological Psychiatry. Recurrent topics in Fiona Forrestal's work include Tryptophan and brain disorders (5 papers), Multiple Sclerosis Research Studies (5 papers) and Alzheimer's disease research and treatments (4 papers). Fiona Forrestal is often cited by papers focused on Tryptophan and brain disorders (5 papers), Multiple Sclerosis Research Studies (5 papers) and Alzheimer's disease research and treatments (4 papers). Fiona Forrestal collaborates with scholars based in United States, Netherlands and Switzerland. Fiona Forrestal's co-authors include Ying Tian, Samantha Budd Haeberlein, Stephen Salloway, Patrick Burkett, Kimberly Umans, Karen Smirnakis, Priya Singhal, Guanfang Wang, Frederik Barkhof and Jerome Barakos and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Annals of Neurology.

In The Last Decade

Fiona Forrestal

17 papers receiving 992 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

2021 411 citations Stephen Salloway, Spyros Chalkias et al. JAMA Neurology profile →
Zuranolone for the Treatment of Postpartum Depression

2023 93 citations Kristina M. Deligiannidis, Samantha Meltzer‐Brody et al. American Journal of Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fiona Forrestal United States	10	305	304	178	167	155	17	1.0k
Jan Mareš Czechia	21	225 0.7×	500 1.6×	356 2.0×	89 0.5×	115 0.7×	60	1.4k
Olawale Osuntokun United States	17	423 1.4×	292 1.0×	359 2.0×	578 3.5×	100 0.6×	27	2.5k
Maja Živković Serbia	22	141 0.5×	120 0.4×	103 0.6×	243 1.5×	148 1.0×	156	1.5k
Antonia Periclou United States	17	117 0.4×	162 0.5×	188 1.1×	395 2.4×	78 0.5×	36	1.2k
Marc L. Gordon United States	18	273 0.9×	104 0.3×	95 0.5×	358 2.1×	42 0.3×	41	1.1k
Francesca Coppola Italy	16	257 0.8×	183 0.6×	141 0.8×	612 3.7×	78 0.5×	28	1.2k
Edward Tobinick United States	22	594 1.9×	116 0.4×	159 0.9×	72 0.4×	58 0.4×	30	1.7k
Wen‐Bin Li China	21	262 0.9×	141 0.5×	43 0.2×	99 0.6×	104 0.7×	64	1.5k
Richard C. Crist United States	22	191 0.6×	157 0.5×	153 0.9×	80 0.5×	47 0.3×	60	1.4k

Countries citing papers authored by Fiona Forrestal

Since Specialization

Citations

This map shows the geographic impact of Fiona Forrestal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Forrestal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Forrestal more than expected).

Fields of papers citing papers by Fiona Forrestal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Forrestal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Forrestal. The network helps show where Fiona Forrestal may publish in the future.

Co-authorship network of co-authors of Fiona Forrestal

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Forrestal. A scholar is included among the top collaborators of Fiona Forrestal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Forrestal. Fiona Forrestal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Cummings, Jeffrey L., Sharon Cohen, Holly M. Brothers, et al.. (2025). Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease. Alzheimer s & Dementia. 21(6). e70224–e70224. 3 indexed citations

Deligiannidis, Kristina M., Samantha Meltzer‐Brody, Robert Lasser, et al.. (2023). Effect of zuranolone on insomnia symptoms in patients with postpartum depression in the SKYLARK study. American Journal of Obstetrics and Gynecology. 228(1). S272–S272. 3 indexed citations

Parikh, Sagar V., Scott T. Aaronson, Sanjay J. Mathew, et al.. (2023). Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 49(2). 467–475. 15 indexed citations

Cutler, Andrew J., Gregory W. Mattingly, Susan G. Kornstein, et al.. (2023). Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 85(1). 8 indexed citations

Clayton, Anita H., Robert Lasser, Sagar V. Parikh, et al.. (2023). Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial. American Journal of Psychiatry. 180(9). 676–684. 50 indexed citations

Deligiannidis, Kristina M., Samantha Meltzer‐Brody, Marlene P. Freeman, et al.. (2023). Zuranolone for the Treatment of Postpartum Depression. American Journal of Psychiatry. 180(9). 668–675. 93 indexed citations breakdown →

Naik, Himanshu, Yuan Zhao, Fiona Forrestal, et al.. (2021). Population Pharmacokinetics of Vixotrigine in Healthy Volunteers and Subjects with Trigeminal Neuralgia, Painful Lumbosacral Radiculopathy and Erythromelalgia. European Journal of Drug Metabolism and Pharmacokinetics. 46(3). 395–404. 5 indexed citations

Herring, William L., Ian Gould, Howard Fillit, et al.. (2021). Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease. Neurology and Therapy. 10(2). 919–940. 31 indexed citations

Salloway, Stephen, Spyros Chalkias, Frederik Barkhof, et al.. (2021). Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurology. 79(1). 13–13. 411 indexed citations breakdown →

10.

Cohen, Sharon, Ping He, Ryan Miller, et al.. (2021). Item‐level analysis of clinical measures in patients with early symptomatic Alzheimer’s disease following treatment with high‐dose aducanumab in the phase 3 study EMERGE. Alzheimer s & Dementia. 17(S9). 1 indexed citations

11.

Shinobu, Leslie A., Michael Polydefkis, Giuseppe Lauria, et al.. (2019). CONVEY, A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study Design of Vixotrigine for the Treatment of Pain in Participants With Confirmed Small Fiber Neuropathy (P2.6-068). Neurology. 92(15_supplement). 1 indexed citations

12.

Kaufman, Michael D., Gabriel Pardo, Howard Rossman, et al.. (2014). Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences. 341(1-2). 22–27. 61 indexed citations

13.

O’Connor, Paul, Andrew Goodman, Ludwig Kappos, et al.. (2014). Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 83(1). 78–86. 104 indexed citations

14.

Morrow, Sarah A., et al.. (2011). Effects of acute relapses on neuropsychological status in multiple sclerosis patients. Journal of Neurology. 258(9). 1603–1608. 64 indexed citations

15.

Polman, CH, Andrew Goodman, Ludwig Kappos, et al.. (2010). Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Multiple Sclerosis Journal. 16(11). 1385–1392. 88 indexed citations

16.

Rudick, Richard A., Paul O’Connor, Chris H. Polman, et al.. (2010). Assessment of JC virus DNA in blood and urine from natalizumab‐treated patients. Annals of Neurology. 68(3). 304–310. 72 indexed citations

17.

Fitzgerald, D. L. & Fiona Forrestal. (1984). Monthly and annual averages of rainfall for Ireland 1951-1980. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact